El golimumab (Simponi - Janssen Inc.) nueva indicación: la colitis ulcerosa

Autores
Categoría Resumen estructurado de revisiones sistemáticas
RevistaHTA Database
Año 2014
Cargando información sobre las referencias

RECORD STATUS:

This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

CITATION:

CADTH. Golimumab (Simponi - Janssen Inc.) new indication: ulcerative colitis Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation. 2014
Epistemonikos ID: c6b6b2770945deea9f1de4f20172a1dbd35257c2
First added on: Feb 06, 2015